Literature DB >> 18992347

Chemokine signaling in cancer: one hump or two?

Joshua B Rubin1.   

Abstract

Chemokines and their receptors play essential roles in the development and function of multiple tissues. Chemokine expression, particularly CXCL12 and its receptor CXCR4, has prognostic significance in several cancers apparently due to chemokine mediated growth and metastatic spread. These observations provide the rationale for pursuing CXCR4 inhibition for cancer chemotherapy. However, the multiple homeostatic functions of CXCR4 may preclude global inhibition as a therapeutic strategy. Here I review CXCR4 signaling and how it might differ in normal and transformed cells with special emphasis on the role that altered CXCR4 counter-regulation might play in tumor biology. I propose that CXCR4 mediates unique signals in cancer cells as a consequence of abnormal counter-regulation and that this results in novel biological responses. The importance of testing this hypothesis lies in the possibility that targeting abnormal CXCR4 signaling might provide an anti-tumor effect without disturbing normal CXCR4 functions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18992347      PMCID: PMC2694237          DOI: 10.1016/j.semcancer.2008.10.001

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  99 in total

Review 1.  In vivo functions of heterotrimeric G-proteins: studies in Galpha-deficient mice.

Authors:  S Offermanns
Journal:  Oncogene       Date:  2001-03-26       Impact factor: 9.867

2.  Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma.

Authors:  S A Rempel; S Dudas; S Ge; J A Gutiérrez
Journal:  Clin Cancer Res       Date:  2000-01       Impact factor: 12.531

3.  Chemokines integrate JAK/STAT and G-protein pathways during chemotaxis and calcium flux responses.

Authors:  Silvia F Soriano; Antonio Serrano; Patricia Hernanz-Falcón; Ana Martín de Ana; María Monterrubio; Carlos Martínez; J Miguel Rodríguez-Frade; Mario Mellado
Journal:  Eur J Immunol       Date:  2003-05       Impact factor: 5.532

4.  Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice.

Authors:  Q Ma; D Jones; P R Borghesani; R A Segal; T Nagasawa; T Kishimoto; R T Bronson; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

5.  Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits.

Authors:  P Crespo; N Xu; W F Simonds; J S Gutkind
Journal:  Nature       Date:  1994-06-02       Impact factor: 49.962

6.  Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas.

Authors:  Chiara Calatozzolo; Emanuela Maderna; Bianca Pollo; Maurizio Gelati; Carlo Marras; Antonio Silvani; Danilo Croci; Amerigo Boiardi; Andrea Salmaggi
Journal:  Cancer Biol Ther       Date:  2006-07-21       Impact factor: 4.742

7.  Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies.

Authors:  B Mark Woerner; Nicole M Warrington; Andrew L Kung; Arie Perry; Joshua B Rubin
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

Review 8.  G-protein signaling: back to the future.

Authors:  C R McCudden; M D Hains; R J Kimple; D P Siderovski; F S Willard
Journal:  Cell Mol Life Sci       Date:  2005-03       Impact factor: 9.261

Review 9.  Chemokines in neuroectodermal cancers: the crucial growth signal from the soil.

Authors:  Nicole Gross; Roland Meier
Journal:  Semin Cancer Biol       Date:  2008-10-28       Impact factor: 15.707

Review 10.  Chemokines in neuroectodermal tumour progression and metastasis.

Authors:  Lizzia Raffaghello; Claudia Cocco; Maria Valeria Corrias; Irma Airoldi; Vito Pistoia
Journal:  Semin Cancer Biol       Date:  2008-11-01       Impact factor: 15.707

View more
  34 in total

1.  CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.

Authors:  Tao Sun; Scott M Gianino; Erin Jackson; David Piwnica-Worms; David H Gutmann; Joshua B Rubin
Journal:  J Neuroimmunol       Date:  2010-07-27       Impact factor: 3.478

2.  Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

Authors:  Jerome Moreaux; Dirk Hose; Alboukadel Kassambara; Thierry Reme; Philippe Moine; Guilhem Requirand; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

Review 3.  The unique structural and functional features of CXCL12.

Authors:  Rik Janssens; Sofie Struyf; Paul Proost
Journal:  Cell Mol Immunol       Date:  2017-10-30       Impact factor: 11.530

4.  Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth.

Authors:  B Mark Woerner; Jingqin Luo; Kristin R Brown; Erin Jackson; Sonika M Dahiya; Paul Mischel; Jeffrey L Benovic; David Piwnica-Worms; Joshua B Rubin
Journal:  Mol Cancer Res       Date:  2011-11-15       Impact factor: 5.852

5.  Reprogramming Medulloblastoma-Propagating Cells by a Combined Antagonism of Sonic Hedgehog and CXCR4.

Authors:  Stacey A Ward; Nicole M Warrington; Sara Taylor; Najla Kfoury; Jingqin Luo; Joshua B Rubin
Journal:  Cancer Res       Date:  2016-12-28       Impact factor: 12.701

6.  Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.

Authors:  Federica Barbieri; Adriana Bajetto; Tullio Florio
Journal:  J Oncol       Date:  2009-12-14       Impact factor: 4.375

Review 7.  Chemokines and the microenvironment in neuroectodermal tumor-host interaction.

Authors:  Rajasekharan Somasundaram; Dorothee Herlyn
Journal:  Semin Cancer Biol       Date:  2008-11-13       Impact factor: 15.707

8.  The Role of chemokine receptor CXCR4 in breast cancer metastasis.

Authors:  Debarati Mukherjee; Jihe Zhao
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

Review 9.  Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

Authors:  Hyunsuk Shim; Shinya Oishi; Nobutaka Fujii
Journal:  Semin Cancer Biol       Date:  2008-11-25       Impact factor: 15.707

10.  PDZ-RhoGEF is essential for CXCR4-driven breast tumor cell motility through spatial regulation of RhoA.

Authors:  Amanda P Struckhoff; Manish K Rana; Swapnil S Kher; Matt E Burow; Joseph L Hagan; Luis Del Valle; Rebecca A Worthylake
Journal:  J Cell Sci       Date:  2013-07-18       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.